Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

894 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants.
Thorsen L, Courneya KS, Stevinson C, Fosså SD. Thorsen L, et al. Among authors: fossa sd. Support Care Cancer. 2008 Sep;16(9):987-97. doi: 10.1007/s00520-008-0411-7. Epub 2008 Feb 15. Support Care Cancer. 2008. PMID: 18274783 Review.
Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment.
Fosså SD, Paus E, Lindegaard M, Newling DW. Fosså SD, et al. Br J Urol. 1992 Feb;69(2):175-9. doi: 10.1111/j.1464-410x.1992.tb15491.x. Br J Urol. 1992. PMID: 1371425
Recombinant interferon alpha-2A combined with prednisone in metastatic renal-cell carcinoma: treatment results, serum interferon levels and the development of antibodies.
Fosså SD, Lehne G, Gunderson R, Hjelmaas U, Holdener EE. Fosså SD, et al. Int J Cancer. 1992 Apr 1;50(6):868-70. doi: 10.1002/ijc.2910500606. Int J Cancer. 1992. PMID: 1372881 Clinical Trial.
89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
Fosså SD, Paus E, Lochoff M, Backe SM, Aas M. Fosså SD, et al. Br J Cancer. 1992 Jul;66(1):177-80. doi: 10.1038/bjc.1992.238. Br J Cancer. 1992. PMID: 1379058 Free PMC article.
The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
Fosså SD, Waehre H, Paus E. Fosså SD, et al. Br J Cancer. 1992 Jul;66(1):181-4. doi: 10.1038/bjc.1992.239. Br J Cancer. 1992. PMID: 1379059 Free PMC article.
Quality of life in prostate cancer patients.
Fosså SD, Kaasa S, da Silva FC, Suciu S, Hengeveld MW. Fosså SD, et al. Prostate Suppl. 1992;4:145-8. doi: 10.1002/pros.2990210523. Prostate Suppl. 1992. PMID: 1574455 Review. No abstract available.
Prognostic factors in hormone-resistant progressing cancer of the prostate.
Fosså SD, Dearnaley DP, Law M, Gad J, Newling DW, Tveter K. Fosså SD, et al. Ann Oncol. 1992 May;3(5):361-6. doi: 10.1093/oxfordjournals.annonc.a058207. Ann Oncol. 1992. PMID: 1616889
Flutamide in hormone-resistant prostatic cancer.
Fosså SD, Hosbach G, Paus E. Fosså SD, et al. J Urol. 1990 Dec;144(6):1411-4. doi: 10.1016/s0022-5347(17)39756-2. J Urol. 1990. PMID: 1700154 Clinical Trial.
DNA ploidy in the primary tumor from patients with nonseminomatous testicular germ cell tumors clinical stage I.
Fosså SD, Nesland JM, Waehre H, Amellem O, Pettersen EO. Fosså SD, et al. Cancer. 1991 Apr 1;67(7):1874-7. doi: 10.1002/1097-0142(19910401)67:7<1874::aid-cncr2820670710>3.0.co;2-6. Cancer. 1991. PMID: 1848470
Glomerular filtration rate, 131I-hippuran clearance and estimated creatinine clearance in cancer patients.
Lindegaard MW, Aass N, Bue ES, Theodorsen L, Fosså SD. Lindegaard MW, et al. Among authors: fossa sd. Br J Cancer. 1991 Aug;64(2):401-5. doi: 10.1038/bjc.1991.317. Br J Cancer. 1991. PMID: 1892774 Free PMC article.
894 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback